Mirtazapine Milpharm Limited

Mirtazapine, the active ingredient in Mirtazapine Milpharm Limited, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adults.

GNH USA supplies Mirtazapine Milpharm Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used in the management of depressive disorders by modulating neurotransmitter activity.

Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. Depressive symptoms with insomnia: helps restore sleep quality alongside mood improvement. Depressive symptoms with anxiety: may alleviate associated anxiety while treating core depression.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Increased appetite and weight gain. - Sedation or drowsiness, especially at treatment initiation. - Dry mouth. - Constipation. - Dizziness. - Edema of the lower extremities.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Hepatotoxicity with elevated liver enzymes. - Severe hypersensitivity reactions, including rash or angioedema. - Suicidal thoughts, particularly in young adults. - Seizures in predisposed individuals. - Uncontrolled hypertension.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Pregnancy: safety not established; weigh potential benefits against risks. - Breastfeeding: excreted in milk; consider alternatives. - Hepatic impairment: dose adjustment may be required. - Elderly patients: increased sensitivity to sedation and falls. - Concomitant CNS depressants: monitor for additive sedation. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - CYP1A2 inhibitors (e.g., fluvoxamine): may increase mirtazapine plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine, tamoxifen): possible altered metabolism. - Anticholinergic agents: additive dry mouth and constipation. - Warfarin: monitor INR for potential changes.